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Clinical outcomes in patients co‑infected
with COVID‑19 and Staphylococcus aureus:
a scoping review
Jenna R. Adalbert1,2*, Karan Varshney2,3, Rachel Tobin3 and Rafael Pajaro4

Abstract
Background: Endemic to the hospital environment, Staphylococcus aureus (S. aureus) is a leading bacterial pathogen that causes deadly infections such as bacteremia and endocarditis. In past viral pandemics, it has been the principal cause of secondary bacterial infections, significantly increasing patient mortality rates. Our world now combats
the rapid spread of COVID-19, leading to a pandemic with a death toll greatly surpassing those of many past pandemics. However, the impact of co-infection with S. aureus remains unclear. Therefore, we aimed to perform a high-quality
scoping review of the literature to synthesize the existing evidence on the clinical outcomes of COVID-19 and S.
aureus co-infection.
Methods: A scoping review of the literature was conducted in PubMed, Scopus, Ovid MEDLINE, CINAHL, ScienceDirect, medRxiv, and the WHO COVID-19 database using a combination of terms. Articles that were in English, included
patients infected with both COVID-19 and S. aureus, and provided a description of clinical outcomes for patients were
eligible. From these articles, the following data were extracted: type of staphylococcal species, onset of co-infection,
patient sex, age, symptoms, hospital interventions, and clinical outcomes. Quality assessments of final studies were
also conducted using the Joanna Briggs Institute’s critical appraisal tools.
Results: Searches generated a total of 1922 publications, and 28 articles were eligible for the final analysis. Of the
115 co-infected patients, there were a total of 71 deaths (61.7%) and 41 discharges (35.7%), with 62 patients (53.9%)
requiring ICU admission. Patients were infected with methicillin-sensitive and methicillin-resistant strains of S. aureus,
with the majority (76.5%) acquiring co-infection with S. aureus following hospital admission for COVID-19. Aside from
antibiotics, the most commonly reported hospital interventions were intubation with mechanical ventilation (74.8 %),
central venous catheter (19.1 %), and corticosteroids (13.0 %).
Conclusions: Given the mortality rates reported thus far for patients co-infected with S. aureus and COVID-19,
COVID-19 vaccination and outpatient treatment may be key initiatives for reducing hospital admission and S. aureus
co-infection risk. Physician vigilance is recommended during COVID-19 interventions that may increase the risk of
bacterial co-infection with pathogens, such as S. aureus, as the medical community’s understanding of these infection
processes continues to evolve.
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Background
Upon passage of the March 11th anniversary of the official declaration of the coronavirus disease 2019 (COVID19) pandemic [1], the causative severe acute respiratory
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syndrome coronavirus 2 (SARS-CoV-2) pathogen has
infected over 181 million individuals and resulted in
more than 3.9 million deaths worldwide as of July 1, 2021
[2]. In addition to rapid spread through high transmission rates [3], infection with COVID-19 can result in
severe complications such as acute respiratory distress
syndrome (ARDS), thromboembolic events, septic shock,
and multi-organ failure [4]. In response to this novel
virus, the clinical environment has evolved to accommodate the complexities of healthcare delivery in the
pandemic environment [5]. Accordingly, a particularly
challenging scenario for clinicians is the management
of patients with common infections that may be complicated by subsequent COVID-19 co-infection, or conversely co-infected with a pathogen following primary
infection with COVID-19 [6]. Bacterial co-infection in
COVID-19 patients may exacerbate the immunocompromised state caused by COVID-19, further worsening
clinical prognosis [7].
Implicated as a leading bacterial pathogen in both community- and healthcare-associated infections, Staphylococcus aureus (S. aureus) is commonly feared in the
hospital environment for its risk of deadly outcomes such
as endocarditis, bacteremia, sepsis, and death [8]. In past
viral pandemics, S. aureus has been the principal cause
of secondary bacterial infections, significantly increasing patient mortality rates [9]. For viral influenza infection specifically, S. aureus co-infection and bacteremia
has been associated with mortality rates of almost 50%,
in contrast to the 1.4% morality rates observed in patients
infected with influenza alone [10]. Given the parallels
between the clinical presentation, course, and outcomes
of influenza and COVID-19 viral infection [11], mortality rates in COVID-19 patients co-infected with S. aureus
may reflect those observed in influenza patients. However, while recent studies have focused on the incidence
and prevalence of COVID-19 and S. aureus co-infection,
the clinical outcomes of patients co-infected with these
two specific pathogens remains unclear given that existing studies consolidate S. aureus patient outcomes with
other bacterial pathogens [12–14].
Given that the literature informing our knowledge of
COVID-19 is a dynamic and evolving entity, the purpose
of this scoping review is to evaluate the current body of
evidence reporting the clinical outcomes of patients coinfected with COVID-19 and S. aureus. To date, there has
been no review focusing specifically on the clinical treatment courses and subsequent outcomes of COVID-19
and S. aureus co-infection. In response to the urgency of
the pandemic state and high rates of COVID-19 hospital
admissions, we aim to identify important areas for further research and explore potential implications for clinical practice.
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Methods
Search strategy and study selection

To provide a scoping review of initial insight into the
breadth of developing data on COVID-19 and S. aureus
co-infection, we followed the five-stage methodology of
scoping review practice presented by Levac, Colquhoun,
and O’Brien [15]. In accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Scoping Reviews [16], we
conducted electronic searches in PubMed, Scopus, Ovid
MEDLINE, CINAHL, ScienceDirect, medRxiv (preprint),
and the WHO COVID-19 database between July 3, 2021
and July 16, 2021. Search terms were combined with the
use of Boolean operators and included subject headings
or key terms specific to COVID-19 (i.e. severe acute respiratory syndrome coronavirus 2 OR SARS-CoV2 OR
2019 novel coronavirus OR 2019-nCoV OR coronavirus
disease 2019 virus OR COVID-19 OR Wuhan coronavirus) and Staphylococcus aureus (i.e. methicillin-resistant
staphylococcus aureus OR MRSA OR methicillin-susceptible Staphylococcus aureus OR MSSA OR staphylococcal infections). A comprehensive list of our scoping terms
and search strategies is included in the Appendix (Ädditional file 1: Table S1). Two independent, experienced
reviewers (JA and KV) screened the titles and abstracts
of eligible studies and performed full-text review on
qualified selections. For this review, we broadly considered articles of any design that included patients infected
with both COVID-19 and S. aureus, provided a description of the timeline and ultimate clinical outcomes for
these patients (i.e. death or discharge from hospital) at
study completion, and were available in English. Studies
were excluded if they did not report final outcomes since
our scoping review purpose was to evaluate the quality of
existing literature that described the clinical course and
mortality rate of patients co-infected with these pathogens. We excluded duplicate records and disagreements
regarding study inclusion were resolved by consensus or
feedback from the senior author.
Data extraction

For the final articles selected, we completed data extraction in duplicate, and any discrepancies were resolved
through discussion or consult with the senior author.
While several studies also included reports on patients
infected with COVID-19 alone or co-infected with an
alternative pathogen, we extracted data solely for patients
with COVID-19 and S. aureus co-infection. Our data
extraction items included study methodology, author
and study location, type of staphylococcal species, onset
of S. aureus infection, S. aureus culture site and infection
source, patient sample size, age, gender, presentation,
comorbidities or additional co-infections, prior history
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Screening

Identification

Identification of studies via databases
Records identified from:
PubMed (n = 100)
Scopus (n = 644)
Ovid MEDLINE (n = 144)
CINAHL (n = 38)
ScienceDirect (n = 168)
WHO COVID-19 (n = 265)
medRxiv (n = 563)

Records removed before
screening:
Duplicate records removed
(n = 597)

Titles and abstracts screened
(n = 1325)

Records excluded (n = 1233)

Full-text articles assessed for
eligibility (n = 92)

Reports excluded (n = 64):
•
•
•

Included

•

Incidence or prevalence study
with no patient-specific
outcome data (n = 57)
Not available in English (n = 3)
History of S. aureus infection
but no current infection (n = 2)
Genome analysis with no
patient data (n = 2)

Studies included in review
(n = 28)

Fig. 1 Process of searching and selecting articlesincluded in the scoping review based on the PRISMA 2020 flow diagram

of S. aureus infection, diagnostic findings, hospital treatments and interventions, complications, total length of
hospital admission, intensive care unit transfer, and final
patient mortality outcomes upon study completion.
Data synthesis and analysis

Microsoft Excel 2016 (Redmond, WA, USA) was used to
collect and chart data extracted from the studies that met
the inclusion criteria. Data was synthesized and analyzed
descriptively, with frequency counts performed for individual and grouped study metrics. The purpose of synthesizing the extracted information through this method
was to create an overview of existing knowledge and

identify gaps in the current literature on COVID-19 and
S. aureus co-infection.
Quality assessment

Given that the majority of existing literature reporting
outcomes data for COVID-19 and S. aureus co-infection
were case reports, we utilized the Joanna Briggs Institute’s critical appraisal tools [17] to provide a metric for
our scoping assessment of the methodological quality of
the included studies. Application of these tools enabled
examination of study quality in the areas of inclusion criteria, sample size, description of study participants, setting, and the appropriateness of the statistical analysis.
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As in previous reviews [18, 19], the tools were modified
to produce a numeric score with case reports assessed
based on an eight-item scale, case series on a ten-item
scale, and cohort studies on an eleven-item scale. Studies
were assessed with the methodological quality tool specific to their design (i.e. case report, case series, cohort)
by two independent reviewers (JA and KV) and discrepancies were resolved through discussion. While debate
exists regarding the minimal number of patients required
for study qualification as a “case series” [20], we considered studies reporting individual patient data as “case
reports” and those reporting aggregate patient data as
“case series.” Our complete quality assessment, including
tools and scores, is available in the Appendix (Additional
file 1: Tables S2–S4).

Results
Our search strategy produced a total of 1922 potential
publications with patients co-infected by COVID-19
and S. aureus. For transparent and reproducible methods, the PRISMA 2020 flow diagram for new systematic reviews was utilized to display the search results
of our scoping review (Fig. 1). Following deduplication
(n = 597) and a comprehensive screen of study titles and
abstracts for irrelevant material (n = 1233), we reviewed
92 full texts for inclusion eligibility. Of these texts, 64
did not include patient outcomes for COVID-19 and S.
aureus co-infected patients: 57 were incidence or prevalence studies with no patient-specific outcomes data,
two included patients with COVID-19 and a history of S.
aureus infection but no current COVID-19 and S. aureus
co-infection, two were genome analysis studies with no
patient data, and three were unavailable in English (Additional file 1: Table S5).
Publication types and geography

Following full-text review, 28 studies qualified for inclusion in our review, resulting in a total of 115 patients.
Of these 28 included studies, 22 were case reports
(describing single patients with individual data), two
were case series (describing 7–42 patients with aggregate data), and four were cohort studies (describing
4–40 patients with aggregate data). Countries of study
publication included the United States (n = 7) [7, 9,
21–25], Italy (n = 7) [26–32], Japan (n = 2) [33, 34],
Iran (n = 2) [35, 36], the United Kingdom (n = 2) [37,
38], Spain (n = 2) [39, 40], Bahrain (n = 1) [41], China
(n = 1) [42], France (n = 1) [43], the Philippines (n = 1)
[44], Korea (n = 1) [45], and Canada (n = 1) [46], with
publication dates ranging from April 15, 2020 to June
16, 2021. Table 1 describes the characteristics of these
included studies and available information on their
respective patient demographics in detail.
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Publication quality

Figure 2 represents the quality assessment scores produced by the Joanna Briggs Institute’s critical appraisal
tools. Scores ranged from 2 to 8 for case reports (out of 8
points total) (n = 22), 6–9 for case series (out of 10 points
total) (n = 2), and 6–8 for cohort studies (out of 11 points
total) (n = 4). The mean quality assessment score for
these publications compared within their respective categories was 6.8 for case reports, 7.5 for case series, and
7.3 for cohort studies. In terms of most common study
design limitations, the metric of patient post-intervention
clinical conditions was least clearly described for case
reports, neither of the case series consecutively included
participants, and strategies to address incomplete followup were only reported for one of the four cohort studies.
Patient demographics

For the 115 total patients included in our review that
were co-infected with COVID-19 and S. aureus, their
demographic (Table 1) and clinical data (Table 2) were
described with varying completeness. Staphylococcal species and patient outcomes are reported in both
tables to enable direct comparison with patient demographics and clinical course. Across our patient sample, the mean patient age was 54.8 years (SD = 21.6),
65.3% (n = 75) were male, 32.1% (n = 37) were female,
and 3 patients (2.6%) did not have their gender specified in the study. Patients presented with a diversity of
comorbidities with diabetes mellitus (33.9%, n = 39),
hypertension (32.2%, n = 37), and cardiovascular disease (28.7%, n = 33) reported as the most common.
Five patients presented with no comorbidities and
four studies reported no information on patient medical history related to comorbidities. The most common presenting symptoms reported by patients at
hospital admission included cough (13.9%, n = 16),
fever (13.9%, n = 16), and dyspnea (13.0%, n = 15).
Infection characteristics

In terms of specific staphylococcal species co-infection, 51.3% (n = 59) of patients were infected with
methicillin-sensitive staphylococcus aureus (MSSA)
and 49.6% (n = 57) were infected with methicillinresistant staphylococcus aureus (MRSA), with a single patient co-infected with both MRSA and MSSA.
One patient co-infected with MSSA had a fatal Panton-Valentine Leukocidin toxin-producing strain of
MSSA (PVL-MSSA). In addition to COVID-19 and
S. aureus co-infection, 26.1% (n = 30) of patients
were co-infected with one or more separate pathogens such as Klebsiella pneumoniae (n = 6), Candida
spp. (n = 6), Enterococcus spp. (n = 5), Haemophilus

Iran

Philippines

Edrada

Hamzavi

06/23/20

France

Duployez

Bahrain

Italy

De Pascale

Italy

USA

Cusumano

ElSeirafi

USA

Choudhury

Filocamo

05/07/20

China

Chen

08/05/20

08/01/20

9/10

7/8

6/8

7/8

8/8

8/8

Quality
Assessment

Case report

Case report

Case report

Case report

Case report

6/8

8/8

6/8

6/8

8/8

Prospective cohort 8/11

Case series

Case report

Case report

Case report

Case report

Case report

Study design

Age

1 14

1 50

1 59

1 39

1 35

40 64 (mean)

42 65.6 (mean)

1 73

1 29

1 NR

1 62

1 84

N

Male

Male

Male

Female

Male

Males (n = 33),
Females (n = 7)

Males (n = 21),
Females (n = 21)

Male

Male

Female

Female

Female

Male/Female

MSSA

MSSA

MRSA

MSSA

MSSA (PVLsecreting)

MSSA (n = 14),
MRSA (n = 26)

MSSA (n = 23) and
MRSA (n = 19)

MSSA

MSSA and MRSA

MSSA

MSSA

MSSA

Type

None

None

None

Influenza B, Klebsiella pneumoniae

None

Bacteroidetes
(n = 18), Proteobacteria (n = 7),
Actinobacteria
(n = 3), Tenericutes
(n = 2), Fusobacteria (n = 1)1

Enterococcus faecalis (n = 3), Candida
spp. (n = 2), Klebsiella pneumoniae
(n = 2), Escheria
coli (n = 1), Bacillus
spp. (n = 1), Micrococcus spp. (n = 1),
Staphylococcus
epidermidis (n = 1),
Proteus mirabilis
(n = 1)

None

Haemophilus
influenzae

None

Candida tropicalis

Klebsiella pneumoniae

Co-infection

Discharge

Death

Discharge

Death

Outcome

Cerebral palsy

None

NR

None

None

Diabetes mellitus
(n = 8), cardiovascular disease
(n = 7), lung
disease (n = 7),
immunosuppression (n = 4),
neoplasm (n = 4),
chronic kidney
disease (n = 3)

Death

Discharge

Death

Discharge

Death

Death (n = 26)

Death at 30 days
Hypertension
(n = 28)
(n = 29), diabetes
mellitus (n = 21),
cardiovascular disease (n = 19), lung
disease (n = 7),
chronic kidney
disease (n = 6),
malignancy
(n = 5), end-stage
renal disease
(n = 4), organ
transplant (n = 3),
liver disease (n = 1)

Hospice
Type 2 diabetes
mellitus, chronic
foot osteomyelitis,
aortic stenosis,
prosthetic aortic
valve, atrial fibrillation, prior S. aureus
infection

NR (not reported)

Type 2 diabetes
mellitus

Hypertension

None

Comorbidities

(2021) 21:985

05/11/20

04/16/20

05/31/21

11/12/20

07/04/20

11/01/20

05/20/21

Italy

United Kingdom

Bagnato

Chandran

05/15/20

Japan

Adachi

Publication date

Country

First Author

Table 1 Study and patient characteristics
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Country

Japan

“”

United Kingdom

Canada

USA

USA

Italy

USA

USA

Spain

USA

First Author

Hoshiyama

“”

Hussain

Levesque

Mirza

Patek

Posteraro

Rajdev

Rajdev

Ramos-Martinez

Randall

Table 1 (continued)

12/01/20

07/30/20

09/28/20

09/10/20

09/06/20

04/15/20

11/16/20

07/01/20

05/22/20

“”

11/02/20

Publication date

7/8

7/8

8/8

7/8

6/8

6/8

8/8

“”

6/10

Quality
Assessment

Case report

7/8

Prospective cohort 6/11

Case report

Case report

Case report

Case report

Case report

Case report

Case report

“”

Case series

Study design

Age

1 60

1 60

1 36

1 32

1 79

1 0

1 29

1 53

1 69

1 39

1 47

N

Male

NR

Male

Male

Male

Male

Male

Female

Female

Male

Male

Male/Female

MRSA

MSSA

MSSA

MSSA

MRSA

MSSA

MRSA

MSSA

MSSA

MSSA

MSSA

Type
Previous cerebral
hemorrhage

Comorbidities

None

None

Haemophilus
influenzae

Klebsiella pneumoniae

Morganella
morganii, Candida
glabrata, Acinetobacter baumannii,
Proteus mirabilis,
Klebsiella pneumoniae, Escherichia
coli

Herpes simplex
virus

Multi-drug resistant Pseudomonas

None

None

Discharge

Discharge

Outcome

Hospital

Chronic obstructive lung disease,
coronary artery
disease, hypothyroidism

Type 2 diabetes
mellitus, hypercholesterolemia,
wrist arthritis,
sternoclavicular
arthritis

Hypertension, two
renal transplants
for renal dysplasia

Death

Death

Discharge

Discharge

Death
Type 2 diabetes
mellitus, ischemic
heart disease,
peripheral artery
disease, left leg
amputation

Type 2 diabetes
mellitus

Discharge
Maternal history
of oral herpetic
lesions

Cystic fibrosis with Discharge
moderate obstructive lung disease,
exocrine pancreatic insufficiency,
gastroparesis,
chronic S. aureus

Hypertension,
diabetes mellitus,
dyslipidemia

Death
Prosthetic aortic
valve with reduced
ejection fraction

Group B Streptococ- Hypertension
cus

None

Co-infection
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Italy

Spain

Spoto

Valga

06/11/20

09/30/20

06/23/20

06/16/21

2/8

“”

“”

Quality
Assessment

Case report

Case report

Case report

Retrospective
cohort

“”

6/8

6/8

8/8

8/11

“”

Prospective cohort 7/11

Case report

“”

“”

Study design

Age

1 68

1 55

1 95

4 79 (mean)

1 NR

1 NR

1 70

1 60

1 83

N

Male

Female

Female

Male (n = 3),
Female (n = 1)

NR

NR

Male

Male

Male

Male/Female

MSSA

MSSA

MSSA

MRSA

MRSA

MSSA

MSSA

MRSA

MRSA

Type

None

None

Citrobacter werkmanii

C. albicans (n = 2),
Vancomycinresistant enterococci (n = 2), S.
maltophilia (n = 1)
carbapenemresistant Acinetobacter baumannii
(n = 1),

None

None

None

Hepatitis C

None

Co-infection

Hypertension, type Discharge
2 diabetes mellitus, congestive
heart failure, sleep
apnea, ischemic
heart disease,
chronic kidney
disease

Death
Triple negative,
BRCA1-related,
right breast cancer
with multiple
bone metastasis,
type 2 diabetes
mellitus

Death

Death (n = 3)

NR

Hypertension,
chronic heart
failure, paroxysmal
atrial fibrillation,
dyslipidemia,
chronic kidney
disease, vascular
dementia, sacral
pressure ulcers,
dysphagia

Death

Discharge

Hospital

Death

Death

Outcome

Type 2 diabetes
mellitus

None

NR

Hypertension,
type 2 diabetes
mellitus, cirrhosis

Hypertension,
atrial fibrillation

Comorbidities

(2021) 21:985

Patients were colonized with these bacterial phyla, but no distinction between colonization versus infection was reported

Italy

Spannella

“”

“”

Korea

08/07/20

09/01/20

Italy

Iran

Regazzoni

Sharifipour

Son

“”

“”

“”

“”

“”

“”

Publication date

Country

First Author

Table 1 (continued)
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Fig. 2 Quality assessment scores for includedpublications reported as “yes” or “no” for achieving quality metrics per theJoanna Briggs Institute’s
critical appraisal tools

influenzae (n = 2), Proteus mirabilis (n = 2), Escherichia coli (n = 2). Comprehensive patient co-infection
data are reported in Table 1.
Diagnoses and treatments

Of all 115 reported cases of co-infection with COVID19 and S. aureus, diagnosis of S. aureus infection was
most frequently established by blood culture in our
patient sample (64.3%, n = 74), with S. aureus infections manifesting predominantly in patients as bacteremia (64.3%, n = 74) and pneumonia (55.7%, n = 64),
accompanied by several additional endocarditis/vasculitis (3.5%, n = 4), cellulitis (1.7%, n = 2), and osteomyelitis (0.9%, n = 1) cases. Additionally, two patients
that tested positive for S. aureus with no clear infection source were suspected to be chronic carriers of
the bacterial pathogen. From this variety of infection
presentations, the majority (76.5%, n = 88) experienced hospital-onset S. aureus co-infection following
hospitalization for an initial infection with COVID19, and 19 patients (16.5%) presented with S. aureus
infection at the time of admission that was determined to be community-onset in etiology. Aside from
a standard course of antibiotics, patients received
a diversity of adjuvant treatments during their hospital admission, with the most common interventions including intubation and mechanical ventilation
(74.8%, n = 86), a central venous catheter (19.1%,
n = 22), and corticosteroids (13.0%, n = 15). Table 2
describes the clinical course following hospital admission for each patient in comprehensive detail.

Complications and outcomes
During the hospital course of the 115 co-infected
patients in our review, the most common complications were sepsis or systemic inflammatory response
syndrome (23.5 %, n = 27), acute kidney injury (5.2%,
n = 6), acute respiratory distress syndrome (4.3%,
n = 5), pneumonia (4.3%, n = 5), and multi-organ dysfunction or failure (4.3%, n = 5). Transfer to an intensive care unit during admission was clearly reported
for 53.9% (n = 62) of patients, unnecessary for 4.3%
(n = 5), and not reported for the remaining 41.8%
(n = 48). Patients were admitted for a mean length of
26.2 days (SD = 26.7) to any type of inpatient hospital
unit, with the length of hospital stay not reported in
five cases. Upon analysis of the final outcomes reported
for the hospital course of our co-infected COVID-19
and S. aureus patient sample, 71 (61.7%) patients died,
41 (35.7%) were discharged, two remained hospitalized and in stable condition on study conclusion, and
one patient was placed in hospice care. Table 2 further
details the specific complications presenting in each
patient’s hospital trajectory and Table 3 reports the
final pooled frequencies of patient co-infection characteristics and outcomes.
Discussion
As our evidence base of the outcomes of patients with
COVID-19 infection continues to expand, thorough
review of the various clinical scenarios and environments
inherent to the treatment process of this disease are
crucial for patient care management and improvement.

1 MSSA

1 MSSA and MRSA

1 MSSA

42 MSSA (n = 23) and Blood culture, bacMRSA (n = 19)
teremia (n = 42),
pneumonia
(n = 8), vascular
(n = 3), osteomyelitis (n = 1), skin
(n = 1)

Chandran

Chen

Choudhury

Cusumano

Blood culture,
endocarditis and
bacteremia

Sputum sample,
pneumonia

Blood culture and
tracheal aspirate,
pneumonia (ventilator-associated)
and bacteremia

Blood culture,
bacteremia

1 MSSA

Sputum sample,
pneumonia

Diagnosis

Bagnato

Type

1 MSSA

N

Adachi

First Author

Table 2 Clinical characteristics

Cystitis and pyelonephritis on CT,
epidural abscess
(L4/5) on magnetic resonance
imaging (MRI)
Abnormal
CXR (n = 36),
vegetation on
transthoracic echo
(n = 1)

Altered mental
status, low back
pain, urinary
incontinence,
right foot ulcers
Not reported (NR)

Unclearb

Hospitalonset (n = 28),
community-onset
(n = 14)

NR (not reported)

NR

Endocarditis, aortic root abscess

NR

Antibiotics, oral
rifampin, hydroxychloroquine

Antibiotics
(n = 42), intubation and ventilation (n = 31),
central venous
catheter (n = 19)

NR

NR

No

Pneumonia

Antibiotics,
corticosteroids,
lopinavir/ritonavir,
Abidol combined
with IFN inhalant,
Thymalfasin, ribavirin, loratadine

Patchy consolidation and ground
glass opacities in
right upper lobe
on CXR (day 29)

Asymptomatic
(positive COVID
test)

Hospital-onset

51

Yes

Bilateral cavitating 15
lung lesions,
septic shock

Antibiotics,
intubation and
ventilation

Bilateral interstitial
infiltrates (CXR)
and ground glass
opacities (CT)

Dyspnea (positive
COVID test)

Hospital-onset

Yes

140

Psychomotor
agitation and
temporospatial
disorientation,
myopathy

Antibiotics,
corticosteroids,
intubation and
ventilation, antifungals, lopinavir/
ritonavir, hydroxychloroquine,
tocilizumab,
neuromuscular
blocking agents,
olanzapine

ICU

Yes

Length of stay

16

Complications

ARDS

Treatments and
Interventions
Antibiotics,
corticosteroids,
lopinavir/ritonavir,
morphine

Bilateral opacities
on chest x-ray
(CXR), ground
glass opacities
& lower lobe
consolidation on
chest computed
tomography (CT)

Fever, cough, diar- Unremarkable
rhea, myalgia
head CT, normal
creatine kinase

Fever, diarrhea,
dyspnea

Uncleara

Dx findings

Hospital-onset

Presentation

Co-infection
onset

Death at 30 days
(n = 28)

Hospice

Discharge

Death

Discharge

Death

Outcome

Adalbert et al. BMC Infect Dis
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40 MSSA (n = 14),
MRSA (n = 26)

1 MSSA (PVLsecreting)

1 MSSA

1 MRSA

1 MSSA

1 MSSA

1 MSSA

1 MSSA

1 MSSA

De Pascale

Duployez

Edrada

ElSeirafi

Filocamo

Hamzavi

Hoshiyama

“”

Hussain

Type

N

First Author

Table 2 (continued)

Blood culture,
bacteremia

Throat swab and
sputum sample

Throat swab and
sputum sample

Blood culture,
bacteremia

Blood culture,
bacteremia

Blood culture,
bacteremia

Nasal and throat
swab with PCR

Pleural drainage
sample, pneumonia

Tracheal aspirate
and blood culture,
pneumonia
(ventilator-associated) (n = 40)
and bacteremia
(n = 19)

Diagnosis

Fever, cough,
dyspnea, lethargy
Cough
Cough

Uncleard

Uncleare
Uncleare
Community-onset Fever, cough,
dyspnea, malaise

Fever, dyspnea

Fever, dry cough,
dyspnea

Hospital-onset

Hospital-onset

Dry cough, sore
throat

Fever, cough,
bloody sputum

Unclearc

Communityonset/carrier

NR

NR

Late hospitalonset (n = 35),
early hospitalonset (n = 5)

Oseltamivir

Antibiotics,
intubation and
ventilation,
extracorporeal
membrane oxygenation (ECMO),
anticoagulation,
upper left lobectomy

Antibiotics
(n = 40), intubation and ventilation (n = 40)

Treatments and
Interventions

Bilateral reticular
enhancement and
heavily calcified
aortic valve with
mass effect on
left atrial wall on
chest CT

Normal labs

Normal labs

Left pleural effusion on CXR

Bilateral ground
glass opacities on
chest CT

No
Yes

18
Bleeding Dieulafoy’s lesion, fast
atrial fibrillation,
acute kidney
injury, multi-organ
failure, intracerebral hematoma
Antibiotics,
intubation and
ventilation,
esophagogastroduodenoscopy,
pantoprazole, amiodarone, heparin

No
NR

NR
NR

NR

Yes

Yes

Progressive chole- 29
static liver injury

NR

Yes

16

Septic shock
with multi-organ
dysfunction

Multi-organ
dysfunction

No

19

Yes

None

17

Yes (n = 40)

11 (mean)

Septic shock
(n = 22), acute
kidney injury
(n = 4)

Necrotizing pneumonia, deterioration of respiratory,
renal, and liver
functions

ICU

Length of stay

Complications

NR

NR

Antibiotics,
intubation and
ventilation

Antibiotics,
intubation and
ventilation,
lopinavir/ritonavir,
hydroxychloroquine, anakinra

Antibiotics, IFN,
Bilateral pulmonary infiltrates and ribavirin, plasma
therapy, tociliARDS on CXR
zumab injections

Unremarkable
chest CT

Consolidation of
left upper lobe,
left pleural effusion, right ground
glass opacities,
bilateral cavitary
lesions on CT

Dx findings

Presentation

Co-infection
onset

Death

Discharge

Discharge

Death

Discharge

Death

Discharge

Death

Death (n = 26)

Outcome

Adalbert et al. BMC Infect Dis
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1 MRSA

1 MSSA

1 MRSA

1 MSSA

Mirza

Patek

Posteraro

Rajdev

Type

1 MSSA

N

Levesque

First Author

Table 2 (continued)

Sputum sample,
pneumonia
(ventilator-associated)

Blood culture,
bacteremia

Wound culture,
cellulitis

Sputum sample

Sputum sample,
pneumonia
(ventilator-associated)

Diagnosis

Fever, cough,
dyspnea

Dyspnea

Hospital-onset

Community- and
hospital-onsetf

Community-onset Fever, erythema
and erosions
of right thumb
and fourth digit,
somnolence,
decreased feeding

Chest pain,
dyspnea

Fever, dry cough,
dyspnea

Hospital-onset

Carrier (chronic)

Presentation

Co-infection
onset

Bilateral consolidations on CXR,
bilateral ground
glass opacities
and pneumomediastinum with
subcutaneous
emphysema on
chest CT

CXR and chest CT
consistent with
pneumonia

Elevated LFTs,
bilateral perihilar
streaking on CXR,
neutropenia

Yes

Yes

7

53

Hypoxic respiratory failure

Hypoxia, left leg
re-amputation,
septic shock

Antibiotics,
acyclovir, nasal
cannula O2

Antibiotics,
antifungals,
hydroxychloroquine, darunavir/
ritonavir
Intubation and
ventilation,
epoprostenol,
hydromorphone,
neuromuscular
blocking agents,
ECMO

Yes

No

6

Meropenemresistant pseudomonas

47

Yes

At least 39

ARDS, ICUacquired neuromyopathy, acute
kidney injury,
thrombocytopenia, intraventricular hemorrhage,
ventilator-associated pneumonia

Antibiotics,
intubation and
ventilation,
corticosteroids,
propofol, fentanyl,
neuromuscular
blocking agents,
heparin, continuous platelet
infusion, blood
transfusions, IVIG,
endobronchial
clot removals,
romiplostim,
vincristine

Anemia, epistaxis,
oropharyngeal
bleeding, ARDS

ICU

Length of stay

Complications

Treatments and
Interventions

Antibiotics, remBilateral upper
desivir
lobe bronchial
wall thickening
and bronchiectasis
with nodular and
interstitial opacities on chest CT

Small intraventricular hemorrhage on head CT
(day 39)

Dx findings

Discharge

Death

Discharge

Discharge

Hospital

Outcome

Adalbert et al. BMC Infect Dis
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1 MSSA

1 MRSA

1 MRSA

1 MRSA

1 MSSA

1 MSSA

1 MRSA

4 MRSA

Ramos-Martinez

Randall

“”

“”

Regazzoni

Sharifipour

“”

Son

Type

1 MSSA

N

Rajdev

First Author

Table 2 (continued)

Bilateral pneumonia (positive
COVID test)

Cough, dyspnea,
sore throat

Cough, dyspnea,
sore throat

Hospital-onset

Hospital-onset

Hospital-onset

Pneumonia (positive COVID test)

Hypoxia (positive
COVID test)

Hypoxia (positive
COVID test)

Fever, cough,
dyspnea

Hospital-onset

Hospital-onset

Hospital-onset

Sputum sample,
Hospital-onset
pneumonia (n = 4) (n = 4)

Tracheal aspirate,
pneumonia
(ventilator-associated)

Tracheal aspirate,
pneumonia
(ventilator-associated)

Nasal swab and
blood culture,
bacteremia

Blood culture,
bacteremia

Blood culture,
bacteremia

Blood culture,
bacteremia

Fever, meningitis,
right infrapopliteal deep vein
thrombosis

Yes

At least 20

NR

NR

NR

Antibiotics (n = 4),
corticosteroids
(n = 4)

Antibiotics,
intubation and
ventilation

Antibiotics,
intubation and
ventilation

13

9

42 (mean)

Ventilator-associated pneumonia

Ventilator-associated pneumonia

NR

Yes

Yes

Yes

NR

At least 10
Severe systemic
inflammatory
response

Antibiotics, corticosteroids

Ischemic areas
with hemorrhagic
transformation on
head CT and MRI,
large vegetations
on aortic valve
with regurgitation
on transesophageal echo

Yes

NR

10

14

Septic shock

Cardiac arrest

3

Respiratory
distress

Corticosteroids

Corticosteroids,
remdesivir, central
venous catheter

Intubation and
ventilation, corticosteroids, central
venous catheter

NR

NR

23

Hypoxic respiratory failure,
Guillan Barré
syndrome

Antibiotics,
intubation and
ventilation,
corticosteroids,
tacrolimus,
mycophenolate,
remdesivir
Native valve
Antibiotics,
endocarditis, prointubation and
ventilation, central gressive sepsis
venous catheter,
corticosteroids,
tocilizumab

ICU

Length of stay

Complications

Treatments and
Interventions

NR

NR

NR

Mild mitral insufficiency on transthoracic echo

Dx findings

Blood culture, bac- Hospital-onset
teremia (central
venous catheterassociated)

Presentation
Fever, cough,
Diffuse bilateral
dyspnea, myalgias pulmonary opacities on CXR

Co-infection
onset
Hospital-onset

Tracheal aspirate,
pneumonia

Diagnosis

Death (n = 3)

Death

Discharge

Hospital

Death

Death

Death

Death

Discharge

Outcome

Adalbert et al. BMC Infect Dis
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Timeline of blood culture unclear

Timeline of sputum testing unclear

Positive sputum on admission, subsequent ventilator-associated infection

Patient was receiving routine treatments in a healthcare-setting

d

e

f

g

Patient recently treated for S. aureus prior to admission, but setting is unclear

Pleural fluid tested on day 4

Hospital-onset

Fever, dry cough

NR

Bilateral ground
glass opacities and
consolidation in
the middle/upper
lobes on chest CT

Fever, dyspnea,
respiratory
distress following
chemoimmunotherapy

Unclearg

Dx findings
Bilateral ground
glass opacities
and multiple areas
of consolidation
on CXR

Presentation

Community-onset Fever, cough,
emesis

Co-infection
onset

c

Tracheal aspirate,
pneumonia

Tracheal aspirate,
pneumonia

Bronchoalveolar
lavage, pneumonia

Diagnosis

b

Positive sputum culture on day 10

1 MSSA

Valga

a

1 MSSA

Spoto

Type

1 MSSA

N

Spannella

First Author

Table 2 (continued)

Antibiotics,
intubation and
ventilation,
corticosteroids,
hydroxychloroquine, lopinavir/
ritonavir, IFN beta,
heparin

NR

Yes

5

ARDS, multi-organ 47
failure

ARDS

Yes

27

Atrial fibrillation,
respiratory failure,
altered mental
status, tachycardia, severe
hypoxemia

Antibiotics, metoprolol, amiodarone, continuous
positive-pressure
airway
Antibiotics,
intubation and
ventilation,
lopinavir-ritonavir,
hydroxychloroquine

ICU

Length of stay

Complications

Treatments and
Interventions

Discharge

Death

Death

Outcome

Adalbert et al. BMC Infect Dis
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Table 3 Pooled
frequencies
of
characteristics and outcomes (n = 115)

patient
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co-infection

Table 3 (continued)
Total (%)

Total (%)

Gender

Acute kidney injury

6 (5.2

Acute respiratory distress syndrome

5 (4.3)

Male

75 (65.3 )

Pneumonia

5 (4.3)

Female

37 (32.1)

Multi-organ dysfunction/failure

5 (4.3)

Bleeding/coagulopathy

5 (4.3)

Hypoxic respiratory failure

3 (2.6)

Unspecified

3 (2.6)

Staphylococcal Species
MSSA

59 (51.3)

Myopathy/neuropathy

3 (2.6)

MRSA

57 (49.6)

Abscess formation

2 (1.7)

Confusion and altered mental status

2 (1.7)

Co-infection
Klebsiella pneumoniae

6 (5.2)

Atrial fibrillation

2 (1.7)

Candida spp.

6 (5.2)

Endocarditis

2 (1.7)

Enterococcus spp.

5 (4.3)

Anemia

1 (0.9)

Hemophilus influenzae

2 (1.7)

Cardiac arrest

1 (0.9)

Escherichia coli

2 (1.7)

Thrombocytopenia

1 (0.9)

Proteus mirabilis

2 (1.7)

Re-amputation

1 (0.9)

Acinetobacter baumannii

2 (1.7)

Cholestatic liver injury

1 (0.9)

Bacillus spp.

1 (0.9)

Not reported

3 (2.6)

Staphylococcus epidermidis

1 (0.9)

ICU

Micrococcus spp.

1 (0.9)

Yes

Pseudomonas spp.

1 (0.9)

No

Morganella morganii

1 (0.9)

Not reported

Citrobacter werkmanii

1 (0.9)

Outcome

S. maltophilia

1 (0.9)

Death

71 (61.7)

Hepatitis C

1 (0.9)

Discharge

41 (35.7)

Herpes simplex virus

1 (0.9)

Hospital

2 (1.7)

Group B Streptococcus

1 (0.9)

Hospice

1 (0.9)

None

62 (53.9)
5 (4.3)
48 (41.8)

83 (72.2)

S. Aureus Diagnostic Test
Blood culture

74 (64.3)

Tracheal aspirate

46 (40.0)

Sputum sample

11 (9.5)

Nasal swab

2 (1.7)

Lower respiratory tract sample

2 (1.7)

Chronic carrier

2 (1.7)

Wound culture

1 (0.9)

S. aureus Diagnosis
Bacteremia

74 (63.4)

Pneumonia

64 (55.7)

Ventilator-associated

44 (38.3)

Endocarditis/vasculitis

4 (3.5)

Cellulitis

2 (1.7)

Chronic carrier

2 (1.7)

Osteomyelitis

1 (0.9)

Not reported

2 (1.7)

S. AureusInfection Onset
Hospital

88 (76.5)

Community

19 (16.5)

Unclear

7 (6.1)

Complications
Sepsis/Systemic Inflammatory Response Syndrome

27 (23.5)

Given that higher levels of morbidity and death have
been observed in influenza patients co-infected with
multiple pathogens during past pandemics [47], exploring the outcomes of co-infected COVID-19 patients may
establish similar trends and reveal strategies for decreasing the morbidity and mortality of this population in
our current pandemic. Our review of the available clinical data reporting the outcomes of patients co-infected
with COVID-19 and the common bacterial pathogen, S.
aureus, was purposed to augment this knowledge base
and has produced several key findings regarding mortality rate, co-infection onset, and treatment considerations
for these patients.
Foremost, the mortality rate in our review for
patients co-infected with COVID-19 and S. aureus was
61.7%, which depicts a significantly increased mortality rate when contrasted with patients infected solely
by COVID-19 [48]. This outcome is comparable to the
increased morality rates observed in patients acquiring co-infection with S. aureus in addition to influenza
[10], however, our findings emphasize an important
difference in the etiology of COVID-19 and influenza
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co-infection with S. aureus. For influenza specifically,
co-infection with S. aureus is predominantly diagnosed upon patient presentation to a healthcare setting, indicating that the community is a frequent and
supportive environment for the co-infection processes
of these pathogens [9, 49]. In contrast, our findings
indicate that co-infection with S. aureus predominantly occurs in the hospital environment for patients
with COVID-19 infection. The terminology used to
differentiate these infection etiologies is “communityassociated” versus “healthcare-associated,” with delineation between these diagnoses occurring at 48-hours
after admission to a hospital or healthcare facility [50].
Given that co-infection with COVID-19 and S. aureus
occurred after hospital admission in 76.5% of the
patients in our review, preventative measures in the
community-setting or treatment in an outpatient environment may be important considerations for mortality reduction from healthcare-associated S. aureus
infection.
Importantly, while the predominance of S. aureus coinfections occurring after patient admission for COVID19 infection is likely associated with a wide diversity of
patient- and environment-specific factors, our findings suggest that this infection sequence may be partly
attributed to the COVID-19 treatment course. The most
common patient interventions identified in our review
included intubation and mechanical ventilation, central venous catheter placement, and corticosteroids,
which are each associated with increased risks of bacterial infection through introduction of a foreign body or
immunosuppressive properties that dually support bacterial growth [51, 52]. Although these first-line treatments for decompensating patients that present with
severe COVID-19 infection may predispose patients to S.
aureus bacterial co-infection and subsequently increased
mortality rates, they are often unavoidable during the
patient treatment course. Vigilant management surrounding these interventions in patients with COVID-19
infection, such as timely central line or ventilator removal
and prudent steroid dosing, are key quality improvement
practices that warrant routine physician adherence during patient treatment processes given co-infection mortality rates.
In contrast to COVID-19 infection alone, the increased
patient morbidity and mortality of COVID-19 and
healthcare-associated S. aureus co-infection identified
in our review have important implications for future
research and clinical practice. While of clear and crucial
public health importance, our findings further emphasize the imperative of COVID-19 vaccination to reduce
both infection and symptom severity that may predispose patients to the necessity of hospital interventions
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and subsequent S. aureus co-infection. The effectiveness
of this strategy is exemplified by the reduction in influenza and S. aureus pathology observed with increased
influenza vaccination [53, 54]. As seen with influenza coinfection, vaccination may be a crucial harm reduction
measure given that no S. aureus prophylaxis exists, and
the incidence of S. aureus strains refractory to antibiotics
is rising [55]. Additionally, the mortality trends observed
in COVID-19 patients co-infected with S. aureus highlight the necessity for future reviews and clinical studies
focused on the co-infection outcomes of other bacterial and viral pathogens alongside COVID-19. Further
research may inform our ability to predict the trajectory
of patients with various co-infections and identify infection patterns that influence treatment decisions.
To our knowledge, this is the first study to review
and evaluate the outcomes of patients co-infected with
COVID-19 and S. aureus. However, we acknowledge
several limitations to this review. First, the majority of
the studies included in our review were individual case
reports due to the recent emergence of COVID-19 and
limited literature exploring outcomes for patients coinfected with S. aureus. While these types of studies can
be vital for expanding the medical knowledge base and
reveal fundamental disease characteristics, it is crucial
to consider the reporting bias that may exist in this study
design and lack of comparison groups. Per our quality
assessment, trends in study limitations for each type of
publication were variable. Accordingly, our intent for
this review was to pool these outcomes in order to reduce
this bias and transparently report each case for appropriate assessment and application of our findings. In addition, Cusumano et al.’s [9] case series comprised 42 of
the patients in our review and used a study end-point of
death at 30 days, implicating that the true mortality rate
of patients with COVID-19 and S. aureus co-infection
may be higher if related complications necessitate an
extended hospital course. Future high-quality clinical
studies examining patient outcomes are warranted and of
critical importance to further expand on the findings of
our systematic review.

Conclusion
In contrast to patients infected solely with COVID19, co-infection with COVID-19 and S. aureus demonstrates a higher patient mortality rate during
hospital admission. S. aureus co-infection in COVID19 patients is predominantly healthcare-associated, and
common hospital interventions for patients with severe
COVID-19 infection may increase the risk for bacterial infection. Our findings emphasize the imperative
of COVID-19 vaccination to prevent hospitalization for
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COVID-19 treatment and the subsequent susceptibility
to hospital-acquired S. aureus co-infection.
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